Fight the fakes: how to beat the $200bn medicine counterfeiters (3)

7 June, 2019

One way out is to make the big pharma a little bit less greedy. The example of HINARI (Research4Life in general) is that the big publishers provide access to literature at no or very little cost. Developing countries are not asking for free medicine form these giants. They are asking for cooperation to use the license to generics to produce cheaper medicines at home and for these big guys to “compromise” the very high price. They can always make huge amount of money but should not allow for people to die because they cannot afford prices of good medicine. UHC and private sector??

By the way, I have a feeling that HIFA, sometimes, makes free promotion/marketing to some of these medicine. They should pay HIFA every time a brand or a company is mentioned.

Best regards.

Najeeb Al-Shorbaji, PhD, FIAHSI

President of the eHealth Development Association of Jordan,

Independent Consultant in Knowledge Management and eHealth,

e-Marefa Advisor

P.O. Box 542006

Amman 11937

Jordan

Mobile +962 799391604

Tel. +962 (6) 5240273

Skype: Najeeb.al.Shorbaji

Twitter: shorbajin

LinkedIn: https://www.linkedin.com/in/najeeb-al-shorbaji-7a817415/

HIFA profile: Najeeb Al-Shorbaji recently retired from the World Health Organization (WHO), where he has worked since 1988 in different capacities. He was most recently Director of the Knowledge, Ethics and Research Department at WHO headquarters, Geneva. Previously he was Coordinator for Knowledge Management and Sharing in EMRO (Eastern Mediterranean Regional Office), Egypt. He is a member of a number of national and international professional societies and associations specialised in information management and health informatics. He has authored over 100 research papers and articles presented in various conferences and published in professional journals. He is a member of the HIFA Steering Group. http://www.hifa.org/support/members/najeeb shorbajin@gmail.com